1. Home
  2. CMS vs NTRA Comparison

CMS vs NTRA Comparison

Compare CMS & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CMS Energy Corporation

CMS

CMS Energy Corporation

HOLD

Current Price

$69.45

Market Cap

21.2B

Sector

Utilities

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$254.90

Market Cap

27.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMS
NTRA
Founded
1987
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Power Generation
Medical Specialities
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.2B
27.0B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
CMS
NTRA
Price
$69.45
$254.90
Analyst Decision
Buy
Strong Buy
Analyst Count
13
15
Target Price
$78.83
$242.87
AVG Volume (30 Days)
2.2M
1.1M
Earning Date
02-05-2026
02-26-2026
Dividend Yield
3.08%
N/A
EPS Growth
N/A
N/A
EPS
3.47
N/A
Revenue
$8,295,000,000.00
$2,116,676,000.00
Revenue This Year
$8.76
$33.18
Revenue Next Year
$3.99
$16.81
P/E Ratio
$20.28
N/A
Revenue Growth
10.96
38.17
52 Week Low
$63.97
$125.38
52 Week High
$76.45
$249.15

Technical Indicators

Market Signals
Indicator
CMS
NTRA
Relative Strength Index (RSI) 41.04 74.90
Support Level $68.64 $225.83
Resistance Level $70.91 $237.04
Average True Range (ATR) 0.89 5.70
MACD 0.10 1.09
Stochastic Oscillator 36.17 95.22

Price Performance

Historical Comparison
CMS
NTRA

About CMS CMS Energy Corporation

CMS Energy is an energy holding company with three principal businesses. Its regulated utility, Consumers Energy, provides regulated natural gas service to 1.8 million customers and electric service to 1.9 million customers in Michigan. NorthStar Clean Energy, formerly CMS Enterprises, is engaged in wholesale power generation, including contracted renewable energy. CMS sold EnerBank in October 2021.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: